A Phase II Open-Label Extension Study To Evaluate The Long-Term Safety And Efficacy Of Fenebrutinib In Patients Previously Enrolled In A Fenebrutinib Chronic Spontaneous Urticaria Study
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Urticaria
- Focus Adverse reactions
- Sponsors Genentech
- 22 Nov 2019 Status changed from recruiting to discontinued.
- 17 Dec 2018 Planned End Date changed from 26 Sep 2020 to 29 Sep 2020.
- 17 Dec 2018 Planned primary completion date changed from 26 Sep 2020 to 29 Sep 2020.